Table 2.
Parameters of the final cox proportional hazards models for PFS and OS based on data in patients with follicular lymphoma in GADOLIN
| Covariate/tertile | HR (95% CI) * | β | SE | RSE |
|---|---|---|---|---|
| PFS, model with exposure as continuous covariate (C mean ) | ||||
| Cmean (as a continuous covariate) | 0.9974 (0.9965 to 0.9983) | −0.0027 | 0.0005 | 17.42 |
| Bone marrow involvement at baseline, yes vs no | 1.689 (1.217 to 2.346) | 0.5244 | 0.1675 | 31.95 |
| PFS, with exposure as categorical covariate (C mean tertiles) | ||||
| Low tertile of Cmean | 0.3695 (0.2219 to 0.6154) | −0.9956 | .2603 | 26.14 |
| Middle tertile of Cmean | 0.4466 (0.2701 to 0.7383) | −0.8062 | 0.2565 | 31.82 |
| High tertile of Cmean | 0.3031 (0.1782 to 0.5156) | −1.194 | 0.2711 | 22.71 |
| Bone marrow involvement at baseline, yes vs no | 1.758 (1.259 to −2.454) | 0.564 | 0.1703 | 30.19 |
| OS | ||||
| Log Cmean (as a continuous covariate) | 0.8484 (0.7731 to 0.9309) | −0.1645 | 0.04736 | 28.8 |
| Age (as a continuous covariate), increase of 1 y | 1.06 (1.034 to 1.086) | 0.05785 | 0.01257 | 21.73 |
| Bone marrow involvement at baseline, yes vs no | 2.401 (1.473 to 3.914) | 0.8759 | 0.2494 | 28.47 |
CI: confidence interval; Cmean: mean obinutuzumab exposure over induction period; FL: follicular lymphoma; HR: hazard ratio; OS: overall survival; PFS: progression‐free survival; SE: standard error; RSE: relative standard error.
Patients in obinutuzumab + bendamustine arm who received <5 obinutuzumab doses (3 cycles) were excluded from this analysis. Cmean tertiles: low = 141–313 μg/mL; middle = 313–400 μg/mL; high = 400–794 μg/mL.
*
Computed as exp(β).